Navigation Links
Medical societies to launch large-scale study on vein filter use
Date:2/1/2013

FAIRFAX, Va.The Society of Interventional Radiology and Society for Vascular Surgery jointly will launch PRESERVEthe first large-scale, multispecialty prospective study to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment.

The studyalong with the formation of the IVC Filter Study Group Foundationare direct actions taken to address the August 2010 FDA medical alert detailing the possibility that retrievable IVC filters could move or break, potentially causing significant health risks for patients. SIR and SVS are in the process of determining a framework for the PRESERVE (PREdicting the Safety and Effectiveness of InferioR VEna Cava Filters) study, with the goal of obtaining a functional view of all filters placed in the United States.

"PRESERVE data will allow a systematic, functional view, representative of all filters placed in the United States, thus, all stakeholdersindividuals, health care professionals, insurers and government regulatorswill be armed with the knowledge they need on patient risk and, subsequently, quality improvement in filter placement, management and retrieval," said SIR President Marshall E. Hicks, M.D., FSIR.

"This is a paradigm-shifting initiative: interventional radiologists and vascular surgeons collaborating to launch a large-scale prospective study evaluating inferior vena cava filters reveals a lot about each specialty's focusand that focus is on patients, first and foremost," noted SVS President Peter Gloviczki, M.D.

The five-year study will evaluate the overall safety and efficacy of filters placed by doctors and intends to enroll 1,800 patients at approximately 50 centers in the United States. Members of the IVC Filter Study Group Foundation collectively discussed ways to respond to the FDA's stated concerns. SIR and SVS are in the process of making a final decision for a contract research organization, completing protocol development and submitting the
'/>"/>

Contact: Ellen Acconcia
eacconcia@sirweb.org
703-460-5582
Society of Interventional Radiology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings
2. Miniature pressure sensors for medical touch
3. Research!America says house funding levels for FY13 could undermine medical progress
4. Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship
5. Medical device, health professionals attend first national conference on value-driven engineering
6. Ultrasensitive biosensor promising for medical diagnostics
7. UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure
8. Tufts Medical Center researchers finds marker in premies saliva predicts readiness to feed by mouth
9. CDS Monarch Deploys DigitalPersona Strong Authentication Solutions for Secure Access to Electronic Medical Records
10. Nuisance seaweed found to produce compounds with biomedical potential
11. MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
(Date:11/3/2014)... Australia report that low birth weight and preterm birth ... replacements in adulthood. Findings published in the American College ... , indicate that low birth weight and pre-term babies ... to OA as adults. , According to the ... are diagnosed with clinical OA. Symptoms of OA range ...
(Date:11/2/2014)... was fascinating to put a flashlight up to our ... Washington University in St. Louis engineers are using a ... to improve imaging of cancerous tissues and to develop ... K. Beare Distinguished Professor of Biomedical Engineering at the ... novel time-reversal technology that allows researchers to better focus ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2Improving imaging of cancerous tissues by reversing time 2
... Louis, MO, May 11, 2009 As the childhood obesity ... early parent and child behaviors contribute to the problem. A ... in the May/June 2009 issue of the Journal of ... signs of satiety in their infants tend to overfeed them, ...
... world,s second largest fish hide out for half ... on May 7th in Current Biology , a ... the iconic species and highlights just how little we ... the researchers said. "While commonly sighted in surface ...
... team of researchers from the United States, the Netherlands ... that are associated with altered kidney disease risk. One ... protein, the most common protein in the urine of ... for almost 60 years, its functions are not well ...
Cached Biology News:Does mom know when enough is enough? 2Disappearing act of world's second largest fish explained 2Study finds novel genetic risk factors for kidney disease 2
(Date:11/21/2014)... 20, 2014 The report, ... Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, ... Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast to ... drivers, threats, opportunities, and challenges. , Browse ... spread through 185 pages and in-depth TOC ...
(Date:11/21/2014)... 21, 2014 2014 Deep Research ... is a professional and in-depth research report on ... information, like its definition, classification, application, and ... This report covers the international market analysis, including ... as the US, Europe, Asia, China, Japan etc. ...
(Date:11/21/2014)... and SAN DIEGO , Nov. ... today announced that President and CEO Marc Hedrick , M.D. ... DATE:   Thursday, December 4, 2014 TIME:    ... here or paste this URL into your browser,s ... that investors pre-register to save time and receive event updates. ...
(Date:11/18/2014)... New Orleans, LA (PRWEB) November 17, 2014 ... developer of build-to-order, open architecture blade-based and rackmount ... new NVIDIA® Tesla® K80 dual-GPU accelerator throughout its ... Utilizing a pair of the company‚Äôs latest proprietary ... up to eight discrete NVIDIA Tesla K80 dual-GPU ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3
... Inc. (Nasdaq: EXEL ) today announced that ... Inc. (Hudson, NY) pursuant to which Exelixis,sold Taconic ... GmbH,for approximately $20 million, subject to certain post-closing ... and commercialization of,genetically engineered mouse models and engineered ...
... LAKE, N.J., Nov. 20 Barr,Pharmaceuticals, Inc. (NYSE: ... Barr,Laboratories, Inc., has initiated a challenge of the ... 10mg, 15mg & 20mg. Focalin XR is manufactured ... Holdings Inc. Barr filed its Abbreviated New ...
... FRANKLIN, Mass., Nov. 20 Echo Therapeutics,Inc. (OTC ... quarter ended September 30, 2007. For the quarter ended ... share, compared to $1,390,000 or,$.49 per share, for the ... 30, 2007, net loss was $10,278,000, or $1.05 per ...
Cached Biology Technology:Exelixis Sells 80% Stake in Artemis to Taconic 2Exelixis Sells 80% Stake in Artemis to Taconic 3Exelixis Sells 80% Stake in Artemis to Taconic 4Barr Confirms Patent Challenge of Focalin(R) XR 2Barr Confirms Patent Challenge of Focalin(R) XR 3Echo Therapeutics Reports Third Quarter 2007 Results 2Echo Therapeutics Reports Third Quarter 2007 Results 3Echo Therapeutics Reports Third Quarter 2007 Results 4Echo Therapeutics Reports Third Quarter 2007 Results 5Echo Therapeutics Reports Third Quarter 2007 Results 6